Charles Schwab Investment Management Inc Intellia Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $519 Billion
  • Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 789,831 shares of NTLA stock, worth $16.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
789,831
Previous 728,295 8.45%
Holding current value
$16.2 Million
Previous $20 Million 11.77%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$20.02 - $27.22 $1.23 Million - $1.68 Million
61,536 Added 8.45%
789,831 $17.7 Million
Q1 2024

May 08, 2024
BUY
$23.82 - $32.8 $668,555 - $920,597
28,067 Added 4.01%
728,295 $20 Million
Q4 2023

Feb 06, 2024
BUY
$23.16 - $32.34 $439,738 - $614,039
18,987 Added 2.79%
700,228 $21.3 Million
Q3 2023

Nov 08, 2023
SELL
$31.62 - $45.78 $8.58 Million - $12.4 Million
-271,476 Reduced 28.49%
681,241 $21.5 Million
Q2 2023

Aug 09, 2023
BUY
$34.58 - $46.03 $2.89 Million - $3.85 Million
83,545 Added 9.61%
952,717 $38.9 Million
Q1 2023

May 11, 2023
SELL
$33.3 - $44.82 $781,184 - $1.05 Million
-23,459 Reduced 2.63%
869,172 $32.4 Million
Q4 2022

Feb 13, 2023
BUY
$33.21 - $62.69 $4.01 Million - $7.56 Million
120,656 Added 15.63%
892,631 $31.1 Million
Q3 2022

Nov 14, 2022
BUY
$53.92 - $71.7 $3.16 Million - $4.2 Million
58,530 Added 8.2%
771,975 $43.2 Million
Q2 2022

Aug 15, 2022
BUY
$38.49 - $76.21 $657,332 - $1.3 Million
17,078 Added 2.45%
713,445 $36.9 Million
Q1 2022

May 13, 2022
BUY
$58.27 - $118.99 $841,768 - $1.72 Million
14,446 Added 2.12%
696,367 $50.6 Million
Q4 2021

Feb 11, 2022
BUY
$100.76 - $138.36 $1.52 Million - $2.09 Million
15,099 Added 2.26%
681,921 $80.6 Million
Q3 2021

Nov 16, 2021
BUY
$132.37 - $176.78 $27.7 Million - $37 Million
209,525 Added 45.82%
666,822 $89.5 Million
Q2 2021

Aug 16, 2021
BUY
$60.88 - $161.91 $1.59 Million - $4.22 Million
26,081 Added 6.05%
457,297 $74 Million
Q1 2021

May 17, 2021
BUY
$46.59 - $83.68 $2.83 Million - $5.09 Million
60,783 Added 16.41%
431,216 $34.6 Million
Q4 2020

Feb 16, 2021
BUY
$18.83 - $63.53 $540,251 - $1.82 Million
28,691 Added 8.4%
370,433 $20.2 Million
Q3 2020

Nov 13, 2020
BUY
$17.47 - $24.93 $715,169 - $1.02 Million
40,937 Added 13.61%
341,742 $6.79 Million
Q2 2020

Aug 14, 2020
BUY
$11.14 - $22.87 $600,746 - $1.23 Million
53,927 Added 21.84%
300,805 $6.32 Million
Q1 2020

May 15, 2020
BUY
$9.44 - $15.58 $25,327 - $41,801
2,683 Added 1.1%
246,878 $3.02 Million
Q4 2019

Feb 07, 2020
BUY
$10.43 - $17.67 $59,398 - $100,630
5,695 Added 2.39%
244,195 $3.58 Million
Q3 2019

Nov 08, 2019
BUY
$13.07 - $18.51 $552,730 - $782,787
42,290 Added 21.55%
238,500 $3.18 Million
Q2 2019

Aug 09, 2019
BUY
$13.88 - $18.41 $183,285 - $243,104
13,205 Added 7.22%
196,210 $3.21 Million
Q1 2019

May 14, 2019
BUY
$12.79 - $17.62 $145,639 - $200,638
11,387 Added 6.64%
183,005 $3.13 Million
Q4 2018

Feb 14, 2019
SELL
$11.39 - $27.13 $24,420 - $58,166
-2,144 Reduced 1.23%
171,618 $2.34 Million
Q3 2018

Nov 13, 2018
BUY
$25.78 - $32.6 $1.13 Million - $1.42 Million
43,654 Added 33.55%
173,762 $4.97 Million
Q2 2018

Aug 08, 2018
BUY
$20.02 - $30.79 $775,234 - $1.19 Million
38,723 Added 42.37%
130,108 $3.56 Million
Q1 2018

May 07, 2018
BUY
$19.43 - $34.95 $238,134 - $428,347
12,256 Added 15.49%
91,385 $1.93 Million
Q4 2017

Jan 17, 2018
BUY
$17.39 - $31.12 $376,267 - $673,343
21,637 Added 37.63%
79,129 $1.52 Million
Q3 2017

Nov 13, 2017
BUY
$15.16 - $25.75 $871,578 - $1.48 Million
57,492
57,492 $1.43 Million

Others Institutions Holding NTLA

# of Institutions
326
Shares Held
88.8M
Call Options Held
673K
Put Options Held
865K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.56B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email